Dr. Patel says telisotuzumab has better efficacy and less toxicity than docetaxel in MET-high second-line NSCLC. He says giving a similar cytotoxic first can blunt the ADC, so he prefers chemoimmunotherapy first and then the MET-directed ADC at progression rather than docetaxel first for those patients.
Dr. Bazanova says she orders both in practice because IHC measures surface protein while NGS reads gene-level changes, and each can trigger different therapy. A high IHC result without a MET mutation or amplification is not discordant; it tells a separate part of the tumor's biology.
Dr. Bazanova cites breast cancer data suggesting resistance is driven substantially by the ADC payload. Because most lung cancer ADCs currently available or in development use topoisomerase inhibitors, she expects back-to-back use to work poorly, and she notes many trials often exclude prior topoisomerase exposure.
Dr. Bazanova says acquired MET overexpression can appear after EGFR-targeted therapy, so her standard practice is to repeat biopsy and order both NGS and IHC at progression. That acquired finding can open use of a MET-directed therapy in patients whose earlier biopsy lacked the target.
Dr. Patel notes that molecular testing is now easier by liquid biopsy, while IHC remains a serial process on limited tissue. When tissue is scarce, he suggests using liquid biopsy up front for diagnosis or NGS and saving the biopsy for PD-L1, MET, and HER2 stains.
Dr. Bazanova says the LUMINOSITY trial's intermediate group, defined as 3+ staining in 25% to 50% of cells, had a 23% response rate and about seven-month median duration. That group is outside the current FDA indication, although the ongoing TELIMET trial now enrolls these patients.
